A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Completed · Phase 2

Conditions studied: Breast Neoplasms

In brief

This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.

Key facts

Study ID

NCT00034489

Run by

Eli Lilly and Company

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• confirmed diagnosis of breast cancer
• measurable disease
• received prior anthracycline and taxane
• life expectancy > 3 months
• acceptable lab results

You may not qualify if…

• >3 prior regimens
• prior treatment with protocol drugs
• prior (pelvic) radiation
• active CNS metastasis
• inability to take oral vitamins

Where it is running

• Study site — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.